Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HTR3A | P46098 | 3/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31429288 | 1.00 | TSHR (0.52) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15882075 | 0.90 | TSHR (0.51) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24247716 | 0.88 | ALDH1A1 (0.48) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8876579 | 0.87 | ELANE (0.51) | HTR3ACNR1CNR2ELANE | |
| SCHEMBL6954629 | 0.87 | HTR3A (0.47) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1128237 | 0.85 | TSHR (0.50) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29805355 | 0.85 | HTR3A (0.57) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15687579 | 0.84 | ELANE (0.56) | KDM4EHTR3AKMT2AHPGDALDH1A1 | |
| SCHEMBL31429442 | 0.84 | ELANE (0.56) | KDM4EHTR3AKMT2AHPGDALDH1A1 | |
| SCHEMBL29805597 | 0.83 | TSHR (0.56) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| EP-0829474-B1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN SEIFUN GROUP INC (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6197769-B1 | SEROTONINE RECEPTORS ANTAGONIST; GASTROINTESTINAL DISORDERS, ANTIARRHYTHMIA AGENTS; INCONTINENCE | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2001-03-06 | — | — | US | disclosed |
| US-6096746-A | Indazole compound containing a monocyclic amine structure | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5945434-A | TREATMENT OF GASTROINTESTINAL DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0708105-B1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0829474-A1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5684003-A | GASTROINTESTINAL DISORDERS OR ANTIULCER AGENTS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-11-04 | — | — | US | disclosed |
| EP-0708105-A1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | TSHR 3257/4885CYP1A2 2485/4885CYP3A4 2060/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | TSHR 1885/4885CYP1A2 585/4885CYP3A4 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.